trending Market Intelligence /marketintelligence/en/news-insights/trending/nh9jsEjZFGLaCowL9NA09g2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

UK regulator recommends J&J's Imbruvica for mantle cell lymphoma

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

UK regulator recommends J&J's Imbruvica for mantle cell lymphoma

The U.K.'s National Institute for Health and Care Excellence recommended Johnson & Johnson's Imbruvica for use within the National Health Service to treat certain lymphoma patients.

The treatment, also known as ibrutinib, was recommended to treat adults with relapsed or refractory mantle cell lymphoma who have had only one previous line of therapy. The regulator recommended the treatment after J&J unit Janssen Biotech Inc. agreed to provide the drug at a discount.

The decision is a reversal of the regulator's August 2016 rejection of Imbruvica in relapsed or refractory mantle cell lymphoma over cost concerns.

Mantle cell lymphoma is a rare non-Hodgkin lymphoma that mostly affects men over 60. Lymphoma, the most common type of blood cancer, affects cells of the immune system.

Imbruvica is jointly developed and commercialized by AbbVie Inc.'s Pharmacyclics LLC and Janssen Biotech.